(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 53.4% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.55%.
Kura Oncology's revenue in 2026 is $71,639,000.On average, 18 Wall Street analysts forecast KURA's revenue for 2026 to be $8,365,741,060, with the lowest KURA revenue forecast at $6,317,894,008, and the highest KURA revenue forecast at $10,812,717,657. On average, 17 Wall Street analysts forecast KURA's revenue for 2027 to be $16,951,464,997, with the lowest KURA revenue forecast at $10,178,868,691, and the highest KURA revenue forecast at $26,345,568,301.
In 2028, KURA is forecast to generate $22,324,977,310 in revenue, with the lowest revenue forecast at $13,544,304,868 and the highest revenue forecast at $39,692,794,079.